Skip to main content

Merck & Co., Inc. Gardasil/Gardasil 9 revenue

  • MRK · NYSE
  • Pharmaceuticals
  • S&P 500
$147.76+0.55%Close 13 Nov 2026 · Market value $361.6B

Gardasil/Gardasil 9 revenue at Merck & Co., Inc. came to $2.0B for the quarter to 30 Sep 2026, up 14.1% from a year earlier.

As Merck & Co., Inc. reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 4 Nov 2026.

By quarter

$1.9BDec 2023$2.2BMar 2024$2.5BJun 2024$2.3BSep 2024$1.6BDec 2024$1.3BMar 2025$1.1BJun 2025$1.7BSep 2025$1.0BDec 2025$1.1BMar 2026$1.2BJun 2026$2.0BSep 2026
Merck & Co., Inc. Gardasil/Gardasil 9 revenue, every reported period
Period endingGardasil/Gardasil 9 revenueChange on a yearFiled
30 Sep 2026$2.0Bup 14.1%4 Nov 2026
30 Jun 2026$1.2Bup 3.8%7 Aug 2026
31 Mar 2026$1.1Bdown 19.4%4 May 2026
31 Dec 2025$1.0Bdown 33.5%24 Feb 2026
30 Sep 2025$1.7Bdown 24.2%5 Nov 2025
30 Jun 2025$1.1Bdown 54.6%5 Aug 2025
31 Mar 2025$1.3Bdown 41.0%2 May 2025
31 Dec 2024$1.6Bdown 17.1%25 Feb 2025
30 Sep 2024$2.3Bdown 10.8%6 Nov 2024
30 Jun 2024$2.5Bup 0.8%5 Aug 2024
31 Mar 2024$2.2Bup 14.0%3 May 2024
31 Dec 2023$1.9Bup 27.4%26 Feb 2024
30 Sep 2023$2.6Bup 12.7%3 Nov 2023
30 Jun 2023$2.5Bup 46.8%7 Aug 2023
31 Mar 2023$2.0Bup 35.1%5 May 2023
31 Dec 2022$1.5Bdown 3.9%24 Feb 2023
30 Sep 2022$2.3Bup 15.1%3 Nov 2022
30 Jun 2022$1.7Bup 35.7%5 Aug 2022
31 Mar 2022$1.5Bup 59.2%5 May 2022
31 Dec 2021$1.5Bup 53.4%25 Feb 2022
30 Sep 2021$2.0Bup 67.9%5 Nov 2021
30 Jun 2021$1.2Bup 88.1%9 Aug 2021
31 Mar 2021$917.0Mdown 16.4%5 May 2021
31 Dec 2020$997.0Mup 43.9%25 Feb 2021
30 Sep 2020$1.2Bdown 10.1%5 Nov 2020
30 Jun 2020$656.0Mdown 26.0%5 Aug 2020
31 Mar 2020$1.1Bup 30.9%6 May 2020
31 Dec 2019$693.0Mdown 16.9%26 Feb 2020
30 Sep 2019$1.3Bup 26.0%5 Nov 2019
30 Jun 2019$886.0Mup 45.7%6 Aug 2019
31 Mar 2019$838.0Mup 27.0%8 May 2019
31 Dec 2018$834.0M—27 Feb 2019
30 Sep 2018$1.0Bup 55.3%6 Nov 2018
30 Jun 2018$608.0Mup 29.6%7 Aug 2018
31 Mar 2018$660.0M—8 May 2018
30 Sep 2017$675.0M—7 Nov 2017
30 Jun 2017$469.0M—8 Aug 2017

Definition

Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.

Other operating KPIs of Merck & Co., Inc.: Keytruda revenue · Livestock revenue · Keytruda Qlex revenue · ProQuad/M-M-R II/Varivax revenue · Winrevair revenue · Companion Animal revenue · Lynparza alliance revenue · Prevymis revenue · Welireg revenue · Lenvima alliance revenue · Capvaxive revenue · RotaTeq revenue · Vaxneuvance revenue · Janumet revenue · Januvia revenue · Ohtuvayre revenue · Reblozyl alliance revenue · Bridion revenue · Adempas/Verquvo alliance revenue · Zerbaxa revenue · Adempas revenue · Delstrigo revenue · Isentress/Isentress HD revenue · Belsomra revenue · financial statements

Every KPI and segment of MRK, in the terminal.

Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.